In the current study, glucagon was found to increase phosphorylation of ERK1/2 in colon cancer cells, and glucagon did not phosphorylate ERK1/2 in GCGR knockdown colon cancer cells, resulting in attenuation of the promoting effect of glucagon on cell growth. This evidence concerns the gene MAPK3 and colonic neoplasm.